Sorrento Therapeutics Completes Concortis Biosystems Buy

San Diego-based Sorrento Therapeutics has completed its acquisition of Concortis Biosystems, the company announced late Thursday. The deal was worth $11.3M. Sorrento said that the buy provides it with comprehensive antibody drug conjugate technology. Sorrento said the move will help complement its existing development programs. The acquisition had originally been announced in November.